Gene therapy is being investigated as a putative treatment option for cardiovascular diseases, including cerebral vasospasm. Because there is presently no information regarding gene transfer to human cerebral arteries, the principal objective of this study was to characterize adenovirus-mediated expres sion and function of recombinant endothelial nitric oxide syn thase (eNOS) gene in human pial arteries. Pial arteries (outer diameter 500 to 1000 J.1m) were isolated from 30 patients un dergoing temporal lobectomy for intractable seizures and were studied using histologic staining, histochemistry, electron mi croscopy, and isometric force recording. Gene transfer experi ments were performed ex vivo using adenoviral vectors encod ing genes for bovine eNOS (AdCMVeNOS) and Escherichia coli j3-galactosidase (AdCMVLacZ). In transduced arteries, studied 24 hours after exposure to vectors, expression of re combinant j3-galactosidase and eNOS was detected by histo chemistry, localizing mainly to the adventitia (n = 4). Immu-Cerebral vasospasm is a prominent delayed pathologic response to the presence of blood in the subarachnoid space. It occurs in approximately one-third of all patients with aneurysmal subarachnoid hemorrhage in which it accounts for more than 20% of overall morbidity and mortality (Dorsch and King, 1994) . Despite extensive investigation, the precise mechanism underlying cerebral vasospasm is unknown, although there is evidence im plicating defective NO-mediated signaling in this pro-
noelectron microscopy localized recombinant eNOS in adven titial fibroblasts. During contractions to U466 19, bradykinin induced relaxations were significantly augmented in AdCMVeNOS-transduced rings compared with control and AdCMVLacZ-transduced rings (P < 0.01; n = 6). The NOS inhibitor L-nitroarginine methylester (L-NAME) caused sig nificantly greater contraction in AdCMVeNOS-transduced rings (P < 0.001; n = 4) and inhibited bradykinin-induced relaxations in control and transduced rings (P < 0.001; n = 6).
The current findings suggest that in AdCMVeNOS-transduced human pial arteries, expression of recombinant eNOS occurs mainly in adventitial fibroblasts where it augments relaxations to NO-dependent agonists such as bradykinin. Findings from the current study might be beneficial in future clinical applica tions of gene therapy for the treatment or prevention of cerebral vasospasm. Key Words: Adenovirus-Cerebral vasospasm Gene therapy-Human pial artery-Nitric oxide.
cess (Moncada et aI., 1991; Cohen, 1995; Onoue et aI., 1998) . This seems plausible given the pivotal role played by NO in the circulation (Brian et aI., 1996; Khurana and Besser, 1997; Hobbs et aI., 1999) . Recent advances in molecular biology have made it possible to increase NO production in the blood vessel wall through gene trans fer, a technique that has considerable therapeutic poten tial. In agreement with the work of Heistad and col leagues (Ooboshi et aI., 1995 (Ooboshi et aI., , 1997 Heistad and Faraci, 1996) , the authors have demonstrated expression and function of recombinant endothelial nitric oxide synthase (eNOS) gene in canine cerebral arteries transduced with AdCMVeNOS (Chen et aI., 1997 (Chen et aI., , 1998 Tsutsui et aI., 1998; Onoue et aI., 1999) . The authors' animal studies have shown that recombinant eNOS gene can be trans ferred into the adventitia of cerebral arteries where its expression augments relaxations to NO-dependent ago nists. However, the authors have no information regard ing gene transfer to human cerebral arteries.
Previously, successful in vitro adenovirus-mediated gene transfer to human vascular tissue has been performed in cultured endothelial and smooth muscle cells (Chan non et aI., 1996) and in relatively large vessels-including isolated saphenous veins; coronary, internal mammary, and extracranial carotid arteries (Rekhter et aI., 1998) ; and radial artery grafts (Cable et aI., 1998) . More re cently, in vivo cardiovascular gene transfer using adeno viral and plasmid vectors in humans has been reported in studies of patients with critical leg ischemia (Isner et aI., 1998; Laitinen et aI., 1998) and severe coronary artery disease (Isner and Losordo, 1999) . There could be sev eral reasons for the absence of information regarding gene transfer to human cerebral arteries. First, the only nonpostmortem human cerebrovascular model is the pial artery that must be rapidly acquired during appropriate neurosurgical resections to retain its natural advantage over postmortem tissue (Toda et aI., 1985) . Second, the use of living pial arteries from humans involves chal lenges generally not found in other studies in which more robust arteries from humans and animals are used. Such challenges include low tissue availability based on un predictable operating schedules and the requirement for exceedingly delicate handling of pial arteries because of their small diameters « I mm) and thin walls. Third, in the setting of gene transfer these difficulties are com pounded by limited access to, and experience with, ap propriate vectors and the need for simultaneous, parallel experiments involving stable, functionally matched arte rial rings.
Given the lack of information regarding human cere brovascular gene transfer, occurrence of species varia tions in vascular reactivity (Hardebo et aI., 1983; Ryman et aI., 1989) and known unique regulatory aspects of the cerebral circulation (Ryman et aI., 1989; Edvinsson et aI., 1993; Brian et ai., 1996; Thorin et aI., 1997; Bevan et aI., 1998) , the authors believed that a systematic gene transfer study needed to be performed using living, intact human cerebral arteries. In the current work, the authors first established a baseline for their gene transfer experi ments by characterizing the morphology and vasomotor reactivity of freshly isolated human pial arteries (includ ing their responses to NO-related compounds). They then used replication-deficient adenovirus encoding LacZ or eNOS cDNA to demonstrate effective expression and function of recombinant trans gene in human pial arteries 24 hours posttransduction. Findings from the current study support the possibility of gene therapy as a treat ment for cerebrovascular diseases.
MATERIALS AND METHODS

Human tissue
The procedures and handling of human tissue were reviewed and approved by the Institutional Review Board of the Mayo Foundation. Human pial arteries were isolated from temporal lobe specimens in patients undergoing surgery at the Mayo Clinic between June 1998, and February 2000, for intractable temporal lobe epilepsy. During this 20-month period, there was a total of 30 patients (18 male and 12 female) from whom viable tissue could be obtained (ages 8 to 73 years, mean age of 39 years). Arteries were harvested within 5 minutes of removal of the temporal lobe and immediately placed in chilled Krebs Ringer bicarbonate solution (control solution: 118.3 mmollL NaCI, 4.7 mmollL KCI, 2.5 mmollL CaCI2, 1.2 mmollL MgS04, 1.2 mmollL KH2P04, 25.0 mmollL NaHC03, 0.0026 mmollL calcium EDTA, and 11.1 mmollL glucose). On aver age, 1 to 2 pial arteries (outer diameter 500 to 1000 I-lm; 1.5 to 2.0 cm in length) were obtained from each specimen. Visual ized using an operating microscope, peri adventitial pia arachnoid tissue and intraluminal blood were carefully re moved and arteries were sectioned into rings 2 to 3 mm in length. Pial arteries from the first 16 of the 30 patients were used for characterization of morphology and vasomotor reac tivity before gene transfer, whereas arteries from the remaining 14 patients were used in gene transfer experiments.
Adenoviral vectors
Recombinant adenovirus containing eNOS cDNA was gen erated as described in detail elsewhere (Spector and Sa maniego, 1995; Chen et aI., 1997 Recombinant adenoviral vector (AdCMVeNOS) was generated by homologous recombination. Stocks were prepared from positive viral plaques, and these were used to generate high titer (1011_101 2 plaque forming units (PFU)/mL) preparations as determined by plaque assay (Gerard and Meidell, 1995) .
Adenovirus containing cDNA for Escherichia coli J3-galacto sidase (AdCMVLacZ) was used in all gene transfer experi ments as a control; it was propagated, isolated, and quantified as described elsewhere (Chen et aI., 1997) .
Gene transfer
Procedures and handling of tissue exposed to recombinant adenoviral vectors were reviewed and approved by the Institu previous work using the same vectors in canine cerebral arter ies (Chen et ai., 1997; Onoue et aI., 1999) .
Histology and histochemistry
After fixation in 10% buffered formalin, certain arterial seg ments were embedded in paraffin and cut into serial 5-l-lm 
Electron microscopy
For electron microscopy, arterial segments were fixed in 4% paraformaldehyde/O.2% glutaraldehyde and embedded in LR White resin. Thin cross-sections of vessels were mounted on 300-mesh nickel grids and stained with uranyl acetate and lead citrate. Examination and photography of stained vascular cells were performed using a CM-IO transmission electron micro scope. For localization of recombinant eNOS protein, certain sections were' prepared using the immunogold indirect labeling technique (Bendayan, 1989 ). After mounting as described above, cross-sections were preincubated for I hour in PBS Tween 20 with 2% normal goat serum and 0.15 mollL glycine and incubated for 2 hours in mouse monoclonal anti-eNOS primary antibody (see above) diluted 1: 250 in PBS-Tween 20.
They were then rinsed thoroughly in PBS-Tween 20, incubated for 60 minutes in goat anti-mouse IgG-serum, conjugated to 15 nm colloidal gold, and rinsed again in PBS-Tween 20. After drying, these immunogold-Iabeled grids were stained and pho tographed as described above. Coptrol specimens were exposed to the same procedure after omission of primary antibody.
Organ chambers
Each ring was connected to an isometric force transducer (Grass FT03; Grass Instruments, West Warwick, RI, U.S.A.)
and suspended in an organ chamber filled with 25 mL of con trol solution (37°C, pH 7.4) aerated with 94% O2:6% CO2, Isometric force was recorded continuously. Suspended arteries were allowed to stabilize in organ chambers for 75 minutes.
Each ring was then gradually stretched in increments of 0.2 g to the optimal point of its length-tension curve (approximately 0.4 to 0.6 g) as determined by contractions to thromboxane A2 analog U46619 (IO� H moIlL). To evaluate relaxation responses, rings were contracted with U466 I 9 (I 0�8 moUL or 2 x I 0�8 moUL) before addition of relaxing compounds. At the conclu sion of each recording and following washout of test com pound, sustained functional integrity of arterial rings was de termined by contraction to U46619 (lO� 6 moIlL), or relaxation to bradykinin (lO� 6 moUL), or both.
Analysis of vascular reactivity
Concentration-response curves were obtained for all com pounds by cumulative addition of the contracting or relaxing substance to the organ chamber solution. The concentration range for each substance tested was determined from experi ments performed in animal models. Arterial rings from a mini mum of six patients were used to analyze the effect of each substance on vasomotor reactivity. To facilitate accurate com parability, several rings cut from the same artery were studied in parallel, and only rings with stable, nonoscillatory (Gokina et aI ., 1996) tone matched for contractions to U46619 (10-8 mollL or 2 x I 0�8 mollL) were used for data analyses. Each ring was exposed to a maximum of two pharmacologic compounds with an intentionally varied order of exposure. 
Drugs
The following pharmacologic compounds were used:
A23187, bradykinin, L-nitroarginine methyl ester (L-NAME), nimodipine, PPV hydrochloride, prostaglandins F2" and 12, 
RESULTS
Baseline morphology and vasomotor reactivity of human pial arteries
Pial arteries derived from temporal lobectomy patients were found to be morphologically normal after histologic and electron microscopic examination (n = 6; Fig. 1 ; normal morphology through hematoxylin and eosin and periodic acid Schiff staining not shown). Vasomotor re sponses to a wide variety of contracting and relaxing compounds could be elicited and readily reproduced in human pial artery rings (Table 1) . Endothelin-I was found to be the most efficacious and potent vasoconstric tor, whereas PPV was found to be the most efficacious vasodilator; nimodipine was the most potent of the non NO-mediated vasodilators studied ( Table I) . The endo thelium-dependent peptides bradykinin and substance P and calcium ionophore A23187 caused concentration dependent relaxations (Table 1 ). Relaxations to bradyki nin (10-11 -3 x 1O� 7 mol!L, -log ECso 8.2 ± 0.5, max relaxation 88 ± 17%, n = 8) were significantly reduced, but not abolished, in the presence of L-NAME (3 x 1O� 4 mol!L, max relaxation 36 ± 39%; P < 0.05; n = 8; Fig. 2A and 2B). The NO donor DEANONOate also producedcon centration-dependent relaxations (Fig. 2C and 2D ). Dur ing contractions to U46619 (l0� 8 mol!L or 2 x 1O� 8 mol/L), relaxation responses to bradykinin (I 0� 11 -3 x 1O� 7 mol/L) were not significantly different in rings in cubated for 24 hours in MEM before isometric force recording compared with nonincubated rings, in which isometric force recording was immediately performed, (P > 0.05; n = 6 and n = 8, respectively; Table 2) . Similarly, contractions to ET-l (10� 11 -3 x 1O� 8 mol/L) were also not significantly different in MEM-incubated rings compared with nonincubated rings (P > 0.05; n 6 and n = 10, respectively; Table 2 ).
Recombinant eNOS gene transfer to human pial arteries
Morphologic evidence. Twenty-four hours after AdCMVLacZ (10 10 PFU/mL) transduction, recombinant l3-galactosidase protein was expressed in all human pial arteries studied histochemically (n = 4; Fig. 3B ). Re combinant eNOS protein was also expressed after 24 hours in all arteries transduced with AdCMVeNOS (10 10 PFUlmL) and studied immunohistochemically (n = 4; Fig. 3C ). Both recombinant proteins were localized predominantly in the adventitial layer, however some endothelial expression was also discernible for each ( Fig. 3B and 3C ). All nontransduced (control) vessels incubated for 24 hours in MEM lacked expression of recombinant l3-galactosidase and eNOS proteins (n = 4; Fig. 3A ). In addition, AdCMVLacZ-transduced vessels did not show positive eNOS immunoreactivity, and AdCMVeNOS-transduced vessels failed to demon strate l3-galactosidase activity and stained negatively when an isotype-matched nonanti-eNOS primary anti- body was used (that is, mouse anti-CD4; data not shown). In AdCMVeNOS-transduced arteries incubated in MEM for 24 hours, immunogold electron microscopy showed recombinant eNOS present in adventitial fibro blasts (Fig. 3D ). In similarly incubated control arteries, no recombinant protein was detected in fibroblasts by immunoelectron microscopy; furthermore, no immuno gold staining was detected in either control or AdCMVeNOS-transduced arteries after omission of the primary antibody (data not shown). The authors were unable to detect endogenous eNOS signal in human pial arteries through immunohistochemistry or immunoelec tron microscopy using mouse monoclonal anti-eNOS antibody at the same dilutions (l :500 and 1 :250, respectively) used to detect recombinant eNOS by these techniques.
Functional evidence. At 24 hours, during contrac tions to U46619 (10-8 moliL or 2 x 10-8 moIlL), relax ation responses to bradykinin (10-11 -3 x 10-7 mollL) in AdCMVLacZ-transduced vessel segments were not (NOS) inhibitor l-nitroarginine methylester (l-NAME, 3 x 10-4 molll). *Differences between control and l-NAME treated rings are statistically significant (P < 0.05). Data are shown as mean ± SD and expressed as percentage of maximal relaxation induced by PPV (3 X 10-4 mol/l, 100% = 0.9 ± 0.3 g). (C) Isometric force recording shows relaxations to increasing concentrations of NO donor diethylamine NONOate (DEANONOate; 10-9 -10-5 molll). No further relaxation could be elicited by PPV (3 X 10-4 molll). At the conclusion of each recording and after washout of test compound, sustained functional integrity of arterial rings was determined by contraction with thromboxane analog U46619 (10-6 mol/l). (0) Concentration-response curve for DEANONOate (10-9 -10-5 mol/l, n = 7 patients). Data are shown as mean ± SD and expressed as percentage of maximal relaxation induced by PPV (3 X 10-4 mol/l, 100% = 0.9 ± 0.3 g). (mol/L) 10-7 -3 X 10-5 10-10 _ 10-5 10-2 -6 X 10-2 10-10 -3 X 10-6 10-1 1 _ 3 X 10-' 10-11 -3 X 10-7 10-9 _ 10-5 10-11 -3 X 10-6 10-10 -3 X 10-6 10-11 -3 X 10-7 10-9 _ 10-5 Compounds are listed in order of increasing efficacy. Data are expressed as mean ± SD. Contractions are expressed as a percentage of maximal contraction induced by 3 x 10-8 mol/L ET -1 (100% = l. l ± 0.5 g).
Relaxations were obtained following contractions to U46619 (10-8 mol/L or 2 x 10-8 mollL) and are expressed as a percentage of maximal relaxation induced by 3 x 10-4 mol/L PPY (100% = 0.9 ± 0.3 g).
significantly different compared with responses of con trol rings (P > 0.05; n = 6; Fig. 4A and 4B) . In contrast, the relaxation effect of bradykinin was significantly aug mented in arterial rings transduced with AdCMVeNOS compared with control and AdCMVLacZ-transduced rings (P < 0.01; n = 6; Fig. 4A and 4B ). The maximum relaxation to bradykinin in control rings was 75 ± II % and the -log ECso was 7.9 ± 0.4. This was not signifi cantly different from the maximum relaxation of 80 ± 11 % and -log ECso of 8.1 ± 0. 5 for AdCMVLacZ transduced rings (P > 0.05; n = 6). However, in AdCMVeNOS-transduced rings, the maximum relax ation was 96 ± 6% and -log ECso 8. 9 ± 0.6; both of these values were significantly different from those observed in control and AdCMVLacZ-transduced rings No significant difference (P > 0.0 5) between arteries in responses to bradykinin (10-11 -3 x 10-7 mol/L) or ET-I (10-11 -3 x 10-8 m01lL).
Data are expressed as mean ± SD. Relaxations were obtained after contractions to U46619 (10-8 mollL or 2 x 10-8 mollL) and are ex pressed as a percentage of maximal relaxation induced by 3 x 10-4 mollL PPY (100% = 0.9 ± 0.3 g and 0.8 ± 0.3 g for nonincubated and 24-hour incubated arteries, respectively). Contractions are expressed as a percentage of maximal contraction induced by 10-6 mol/L U46619 (100% = 1.1 ± 0.5 g and 1.0 ± 0.5 g for nonincubated and 24-hour incubated arteries, respectively). (P < 0.005; n = 6). In control and AdCMVLacZ transduced rings, L-NAME (3 x 10-4 mollL) caused 10 ± 9% and 11 ± 8% contraction, respectively. These val ues were not significantly different from each other (P > 0.05; n = 4), however they were significantly different from the 26 ± 3% contraction caused by L-NAME (3 x 10-4 mollL) in AdCMVeNOS-transduced rings (P < 0.001; n = 4; Fig. 4C ). Furthermore, L-NAME (3 x 10-4 mollL) significantly inhibited relaxations to bradykinin (10-11 -3 x 10-7 mollL) in control and transduced rings (P < 0.001; n = 6; Fig. 4D ). Finally, in gene transfer ex periments in which the effect of ET-l (10-11 -3 x 10-8 moUL) was studied, there were no significant differences between the ECso values and maximum contractions to ET -I in control and transduced rings. For control, AdCMVLacZ-, and AdCMVeNOS-transduced rings, re spectively, the -log ECso values were 9.2 ± 0.6, 9.3 ± 0.3, and 9.1 ± 0.5 (P > 0.05; n = 6); whereas the cor responding maximum contractions were 109 ± 32%, 117 ± 26%, and 108 ± 33% (P > 0.05; n = 6).
DISCUSSION
The current study, whose principal objective was to characterize the expression and function of recombinant eNOS transgene in human pial arteries, was performed for several reasons. First and foremost, there is growing interest in the role of recombinant eNOS gene transfer as a potential therapeutic option in vascular diseases in cluding postsubarachnoid hemorrhage cerebral vaso spasm. Second, to the authors' knowledge, there is no information regarding gene transfer to human cerebral vessels. Third, undertaking the current study represented a logical continuation of the authors' previous work us ing adenoviral vectors in animal cerebral arteries. Lastly, the authors believed that investigation of human cerebral AdCMVLacZ-transduced rings are statistically significant ('P < 0.01; n = 6). Data are shown as mean ± SD and expressed as percentage of maximal relaxation induced by PPV (3 X 10-4 mollL; 100% = 0.8 ± 0.3 g, 0.6 ± 0.3 g, and 0.7 ± 0.2 g for control, AdCMVLacZ transduced, and AdCMVeNOS-transduced rings, respectively). (e) Effect of the NOS inhibitor L-NAME (3 x 10-4 mollL) on resting arterial tone. The difference between AdCMVeNOS-transduced rings compared with control and AdCMVLacZ-transduced rings is statistically significant (*P < 0.001; n = 4). Data are shown as mean ± SD and expressed as percentage of maximal contraction induced by U46619
(10-6 mollL; 100% = 1.1 ± 0.3 g, 1.0 ± 0.6 g, and 1.1 ± 0.3 g for control, AdCMVLacZ-transduced, and AdCMVeNOS-transduced rings, respectively). (0) Concentration-response curves for bradykinin (10-11_3 x 10-7 mollL) in the presence of L-NAME (3 x 10-4 mol/L) in control and AdCMVLacZ-and AdCMVeNOS-transduced rings. There is no statistically significant difference between the curves (P> 0.05; n = 6). Compared with responses in the absence of L-NAME, bradykinin-induced relaxations in the presence of L-NAME were significantly reduced in control and transduced rings (P < 0.001; n = 6). Data are shown as mean ± SD and expressed as percentage of maximal relaxation induced by PPV (3 X 10-4 mollL; 100% = 0.8 ± 0.3 g, 0.6 ± 0.3 g, and 0.7 ± 0.2 g for control, AdCMVLacZ-transduced, and AdCMVeNOS-transduced rings, respectively).
arteries was nece:,csary given the known occurrence of species-and vascular territory-related variations in vaso motor reactivity. The principal findings of this study are that effective adenovirus-mediated ex vivo transfer and expression of recombinant genes can be performed in human pial arteries, the main cellular target of adenoviral transduction and synthesis of recombinant protein ap pears to be adventitial fibroblasts, and expression of recombinant eNOS in pial arteries is associated with augmented relaxations to the NO-dependent agonist bradykinin.
Baseline morphology and vasomotor reactivity of human pial arteries
To establish a structural and functional baseline for their cerebrovascular gene transfer experiments, the authors first studied nontransduced human pial arteries through histology, electron microscopy, and isometric force re cording. The current morphologic data, consistent with previous studies in human cerebral arteries (Marinkovic et aI., 1979; Dahl, 1986; Kallioinen et aI., 1987; Edvins son et aI., 1993; Lee, 1995) , suggest that pial arteries derived from temporal lobectomy specimens have nor mal histologic and cytoarchitectural features, demon strating no evidence for atherosclerosis, inflammation, traumatic injury, or any other pathology. Furthermore, from a functional perspective, the vasomotor effects of compounds tested in pial arteries before gene transfer were found to be similar to those described in the authors' canine studies (Katusic et a!., 1988; Chen et aI., 1997; Onoue et aI., 1999) , with the exceptions of KCl, PGF2" , substance P, and UTP (all of which had poorer efficacy in human pial arteries). Interestingly, UTP was more effective as a vasodilator than a vasocon strictor in human pial arteries, a finding that was in strong contrast to canine cerebral arteries, but was sup ported by the human pial artery study of Hardebo et a!. (1987) and also consistent with the known occurrence of species variability (Hardebo et aI., 1983) . With regard to vasomotor responses to NO-related compounds, confirming previous studies in animal and human cere bral arteries (Wahl et aI., 1983; Katusic et a!., 1988; Peters son et aI., 1995) , the authors observed concen tration-dependent relaxations to the endothelium dependent peptides bradykinin and substance P, calcium ionophore A23187, and the NO donor DEANONOate. These findings, combined with the observed signifi cant reduction of bradykinin-induced relaxations in the presence of L-NAME, indicate the presence of endog enous NO-mediated signaling in these arteries. This is of obvious importance to the applicability of recombi nant eNOS gene transfer experiments in these vessels. However, it should be noted that other mechanisms of relaxation, for example, those mediated by endothelium derived hyperpolarizing factor (EDHF; Vanhoutte, 1999) might also be present in these arteries, as suggested by the authors' observation of L-NAME-insensitive relax ations to bradykinin. Finally, as a prerequisite for gene transfer studies using adenovirus-transduced human pial arteries (involving 24-hour incubation of rings in MEM), the authors compared the vasomotor reactivity of nonincubated versus 24-hour incubated (non trans duced) human pial artery rings. The authors observed similar vascular reactivity between nonincubated versus incubated arteries. This was indicated by the similarity of the ECso values and maximum responses to bradykinin and ET -1 in both of these groups. These findings suggest that vasomotor data acquired from 24-hour incubated human pial arteries (which were exclusively used in the authors' gene transfer experiments; Chen et aI., 1997) are qualitatively and quantitatively similar to data ac-quired from nonincubated arteries-that is, there is no significant change in vascular reactivity attributable to incubation.
Recombinant eNOS gene transfer to human pial arteries Morphologic evidence. From the authors' canine ce rebrovascular gene transfer experiments (Chen et aI., 1997 (Chen et aI., , 1998 Tsutsui et aI., 1998; Onoue et aI., 1999) , they have established marked crossreactivity of mouse monoclonal anti-eNOS antibody with bovine eNOS (synthesized by our AdCMVeNOS vector). In the current study, the authors were able to readily detect recombi nant eNOS signal in AdCMVeNOS-transduced arteries through immunohistochemistry and immunoelectron mi croscopy using this antibody. However, using this anti body at the same dilutions (J :500 and 1 :250, respec tively) used to detect recombinant eNOS through these techniques, the authors were unable to detect endogenous eNOS in human pial arteries. Consistent with the current findings, using the same antibody at a relatively high concentration (that is, a dilution of 1 :50) in a more robust vessel, Cable et aI. (1998) report only minimal presence of endogenous eNOS in human radial artery studied through immunohistochemistry. Furthermore, in an im munoelectron microscopic study of eNOS localization in human cerebral arteries, Fukuda et aI. (1995) , using the same antibody at an even higher concentration (that is, a dilution of 1 :25), report the presence of eNOS not only near the endothelial cell plasmalemma and in the cyto plasm, but also in the nucleus and extracellular regions, such as the basement membrane, and in smooth muscle cells. However, these latter results suggest a relatively nonspecific pattern of antibody labeling, most likely at tributable to the relatively high concentration of antibody used in their study. The precise reason for the lack of crossreactivity of the authors' antibody with human eNOS remains unclear, although despite the authors' in ability to detect endogenous eNOS morphologically they are confident of its presence in these arteries based on their functional data (using NO-related agonists and L NAME) and findings in previous pial artery studies (Wahl et a!., 1983; Petersson et aI., 1995) .
As demonstrated by positive histochemical and immu nohistochemical staining, respectively, transduction of human pial arteries with adenoviral vectors resulted in expression of l3-galactosidase (reporter) and eNOS trans genes in the arterial wall. Expression of recombinant proteins appeared to predominate in the vascular adven titia, a finding consistent with other studies using adeno viral vectors in canine cerebral (Chen et aI., 1997; Tsu tsui et aI., 2000) and human radial (Cable et aI., 1998) arteries and attributable to ex vivo transduction. In the current study, the authors used immunogold electron mi croscopy to identify the cellular target of adenoviral transduction and subcellular localization of recombinant protein. Recombinant eNOS-bound gold particles were detected in adventitial fibroblasts, both in the region of the plasma membrane and in the cytoplasm, but not in the nucleus. This confirmed the current findings in ca nine basilar arteries transduced ex vivo with AdCMVe NOS (Tsutsui et aI., 1998) .
Functional evidence. To examine the effect of adeno viral transduction on vascular reactivity, responses of human pial arteries to bradykinin, L-NAME, and ET-l were studied in parallel in nontransduced (control) and AdCMVLacZ-and AdCMVeNOS-transduced rings. Studies using large-diameter AdCMVeNOS-transduced canine cerebral arteries (Chen et aI., 1997; Onoue et aI., 1998) have demonstrated significant augmentation of re laxations to receptor-mediated NOS activators such as acetylcholine, substance P and bradykinin, and the re ceptor-independent NOS activator calcium ionophore A23l87. Augmentation of relaxations to bradykinin have also been demonstrated in small-diameter AdCMVe NOS-transduced canine brainstem arteries (Tsutsui et aI., 2000) whose relative size and function more closely ap proximate that of arteries used in the current study. Con sistent with these studies, the authors found that relax ations to bradykinin were significantly augmented in Ad CMVeNOS-transduced arteries compared with control and AdCMVLacZ-transduced arteries. Tsutsui et a!. (2000) have shown that in canine brainstem arteries, bra dykinin caused approximately 82% relaxation in non transduced arteries with a -log ECso of approximately 8.7; in AdCMVeNOS-transduced arteries, bradykinin caused only a marginal increase in maximal relaxation (that is, 86%), but left-shifted the -log ECso value by a whole log-unit (that is, approximately 9.7). In the current study, bradykinin caused a similar whole log-unit left ward shift in the ECso value of AdCMVeNOS transduced versus nontransduced arteries, but a greater increase in maximal relaxation (that is, by approximately 20%) to 96%. In addition to species-related variation, this disparity may be explained by the fact that Tsutsui et aI. (2000) used UTP as a contractile agent to study bra dykinin-induced relaxations, whereas the current study used U46619 (as UTP is a poor vasoconstrictor in human pial arteries; Hardebo et aI., 1987) .
In agreement with other vascular gene transfer studies using NOS inhibitors (Ooboshi et aI., 1997; Tsutsui et aI., 1998) , the authors found that L-NAME significantly reduced bradykinin-induced relaxations in control and transduced arteries. Interestingly, the authors observed a significantly greater amount of L-NAME-induced contraction in AdCMVeNOS-transduced arteries com pared with control and AdCMVLacZ-transduced pial ar teries maintained at resting tension before exposure to L-NAME. One possible explanation for this observa tion could be that L-NAME inhibits a greater amount of J Cereb Blood Flow Metab. Vol. 20. No. 9. 2000 basally active NOS in arteries expressing recombinant eNOS. Finally, reduced contractile responses to UTP, ET-l , KCI, and PGF2a have been reported after trans duction with AdCMVeNOS (Chen et a!., 1997; Cable et aI., 1998; Onoue et aI., 1999) , findings which provide additional and encouraging implications for the benefit of recombinant eNOS gene transfer in the setting of va sospasm. In freshly isolated, nontransduced human pial arteries, the authors found UTP, KCI, and PGF2a to have poorer contractile efficacy compared with their effects in canine cerebral arteries, and accordingly elected to test contractile responses to ET -1 in control and trans�uced pial arteries. A significant reduction in ET-l -induced contraction has been reported by Onoue et al. (1999) in canine basilar artery transduced with AdCMVeNOS. In their study, it was proposed that activation of NOS coupled ET A receptors in genetically modified adventitia overexpressing eNOS led to reversal of the normal va soconstrictor effect of ET-l. Unlike Onoue et a!. (1999) , the authors could not demonstrate any significant differ ence between vasomotor responses of control and trans duced human pial arteries exposed to ET-l . This finding could be explained by the absence of ET A receptor ex pression in human pial artery adventitial fibroblasts.
In summary, the current study demonstrates that re combinant eNOS gene can be functionally expressed in human cerebral arteries after ex vivo adenovirus mediated transduction. Transgene expression principally occurs in adventitial fibroblasts, resulting in augmented relaxations to the NO-dependent agonist bradykinin. The authors believe that eNOS gene transfer, by restoring the biosynthesis of NO in diseased blood vessels, may be beneficial in the setting of vascular disorders such as cerebral vasospasm in which defective NO production has been implicated.
